wegovy vs glp 1 Semaglutide GLP-1 vs. Ozempic vs. With FDA approval of Wegovy

Researchers at University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis

Real-world evidence (RWE) was a major contributor in uncovering some of these unexpected benefits

Inflammatory myopathies and beyond: The dual role of neutrophils in muscle damage and regeneration

Higher doses of semaglutide, such as those in Wegovy, are associated with a greater likelihood of fatigue compared to lower doses like Ozempic